Reaction
Metastases To Bone Marrow reporting signals
As of the last recalculation, Metastases To Bone Marrow appears in 497 FAERS reports alongside 34 co-occurring drug terms. The strongest observed disproportionality signal is BLINATUMOMAB (PRR 53.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Blinatumomab | 13 | 53.6 | 53.6 |
| Ribociclib | 36 | 51.4 | 51.5 |
| Fulvestrant | 35 | 47.7 | 47.7 |
| Bendamustine Hydrochloride | 11 | 39.3 | 39.4 |
| Gemcitabine | 32 | 36.3 | 36.3 |
| Goserelin | 11 | 35.1 | 35.1 |
| Melphalan | 18 | 34.3 | 34.4 |
| Gemcitabine Hydrochloride | 40 | 34.2 | 34.3 |
| Letrozole | 44 | 32.7 | 32.7 |
| Granisetron Hydrochloride | 8 | 32.6 | 32.6 |
| Granisetron | 8 | 32.4 | 32.5 |
| Lanreotide Acetate | 6 | 32.4 | 32.5 |
| Anastrozole Tablets | 16 | 32.2 | 32.3 |
| Letrozole Tablets | 34 | 31.7 | 31.7 |
| Melphalan Hydrochloride | 18 | 31.2 | 31.2 |
| Zoledronic Acid | 27 | 29.7 | 29.7 |
| Cytarabine | 37 | 27.8 | 27.8 |
| Bicalutamide | 9 | 25.2 | 25.2 |
| Doxorubicin Hydrochloride | 18 | 23.9 | 23.9 |
| Pertuzumab | 15 | 23.8 | 23.8 |
| Temozolomide | 11 | 22.3 | 22.3 |
| Doxorubicin | 43 | 22.0 | 22.0 |
| Ifosfamide | 11 | 21.9 | 21.9 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 6 | 19.3 | 19.3 |
| Docetaxel Anhydrous | 27 | 17.7 | 17.7 |
| Docetaxel | 27 | 17.7 | 17.7 |
| Erlotinib | 4 | 17.4 | 17.4 |
| Dabrafenib | 8 | 16.1 | 16.2 |
| Oxaliplatin | 27 | 16.1 | 16.1 |
| Trametinib | 8 | 14.1 | 14.1 |
| Fam-Trastuzumab Deruxtecan-Nxki | 3 | 12.5 | 12.5 |
| Olaparib | 6 | 12.1 | 12.1 |
| Osimertinib | 9 | 12.0 | 12.0 |
| Abiraterone Acetate | 11 | 11.4 | 11.4 |